GlobeNewswire

Sampo plc: Managers’ Transactions (Tetrao SPF)

Share

SAMPO PLC                        MANAGERS’ TRANSACTIONS                 31 August 2020 at 8:45 am

Sampo plc: Managers’ Transactions (Tetrao SPF)

Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the Market Abuse Regulation.

____________________________________________

Person subject to the notification requirement
Name: TETRAO SPF
Position: Closely associated person
(X) Legal person

(1): Person Discharging Managerial Responsibilities In Issuer
Name: Björn Wahlroos
Position: Member of the Board

Issuer: Sampo plc
LEI: 743700UF3RL386WIDA22

Notification type: INITIAL NOTIFICATION
Reference number: 743700UF3RL386WIDA22_20200831065335_3
____________________________________________

Transaction date: 2020-08-27
Venue: OFF-EXCHANGE TRANSACTIONS (XOFF)
Instrument type: DEBT INSTRUMENT
ISIN: XS2226645278
Nature of the transaction: ACQUISITION

Transaction details
(1): Volume: 3,000,000 Unit price: 0.99448 EUR

Aggregated transactions
(1): Volume: 3,000,000 Volume weighted average price: 0.99448 EUR

SAMPO PLC

Jarmo Salonen
Head of Investor Relations and Group Communications
tel. +358 10 516 0030

Distribution:

Nasdaq Helsinki
London Stock Exchange
Financial Supervisory Authority
The principal media
www.sampo.com


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Incap Corporation: Notification in accordance with Chapter 9, Section 10 of the Securities Market Act on a Change in Holdings (Nordea Bank Abp)23.11.2020 20:30:00 CETPress release

Incap Corporation Stock Exchange Release 23 November 2020 at 9.30 p.m. (EET) Notification in accordance with Chapter 9, Section 10 of the Securities Market Act on a Change in Holdings (Nordea Bank Abp) Incap Corporation has on 23 November 2020 received a notification in accordance with the Securities Market Act, according to which the total holdings of shares and votes of Nordea Bank Abp and the entities controlled by it (Nordea Life Assurance Finland Ltd and Nordea Livförsäkring Sverige AB (publ)) in Incap Corporation (FI0009006407) has decreased below 10 percent threshold. Shareholder: Nordea Life Assurance Finland Ltd and Nordea Livförsäkring Sverige AB (publ) Position of previous notification: 14.7 % out of all shares and votes Date of change in holdings: 20 November 2020 Resulting situation on the date on which threshold was crossed: 581,835 shares, i.e. 10 % out of all shares and votes Incap Corporation's total number of shares amounts to 5,820,224 and each share has one vote. Af

EPH European Property Holdings Limited (EPH) announces plans to issue and offer up to 4,500,000 new ordinary shares23.11.2020 19:00:00 CETPress release

23 November 2020, Road Town, Tortola, BVI EPH European Property Holdings Ltd (the "Company"), an investment company listed on SIX Swiss Exchange which holds an extensive property portfolio with a total value of around USD 1.3 billion across Europe, announces its intention to issue and offer up to 4,500,000 new ordinary shares for a consideration equaling the last reported net asset value (as per 30 June 2020) in the amount of USD 38.82 per share (the "Offer Shares"). EPH will hold a virtual conference on Monday, 30 November 2020 at 3 pm CET to explain details of the capital increase and the company's strategy. You are welcome to register for this event. Please contact corporatefinance@valartis.chto receive dial-in data. The proceeds from the issue of the Offer Shares will be used for funding our future growth through, including, without limitation, the following: acquisition of additional income generating or to be developed commercial properties and investments in our existing real es

Idorsia announces positive results of the two Japanese registration studies with clazosentan23.11.2020 17:45:10 CETPress release

Clazosentan demonstrates significant reduction of vasospasm-related morbidity and all-cause mortality in patients following aneurysmal subarachnoid hemorrhage (aSAH)Clazosentan demonstrates significant reduction of all-cause morbidity and mortality in patients following aSAH in a pre-planned pooled analysis of data from both studies.Idorsia Japan to file New Drug Application (NDA) with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in the first half of 2021Global Phase 3 study “REACT” investigating the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in adult patients following aSAH continues to actively recruit Allschwil, Switzerland – November 23, 2020 Idorsia Ltd (SIX: IDIA) today announced positive top-line results of the Japanese registration program investigating clazosentan in adult Japanese patients post-aSAH. The program consisted of two double-blind, randomized, placebo-controlle

Saniona rapporterar positiva topline-resultat från den öppna förlängningen av Fas 2-studien med Tesomet mot hypotalamisk fetma23.11.2020 17:00:00 CETPressemelding

PRESSMEDDELANDE 23 november 2020 Tesomet tolererades väl av patienterna med hypotalamisk fetma under hela den 48 veckor långa studien (24 veckor dubbelblind del följt av 24 veckor öppen förlängning). Inga kliniskt betydelsefulla skillnader kunde noteras avseende hjärtfrekvens eller blodtryck och samtliga patienter som påbörjade den öppna förlängningsstudien slutförde också studien.De patienter som fick Tesomet under hela den 48 veckor långa studietiden påvisades statistiskt signifikanta och kliniskt meningsfulla minskningar av kroppsvikt och midjeomfång från baseline till vecka 48, liksom förbättrad glykemisk kontroll. De förbättringar som observerades under den första dubbelblinda delen av studien bibehölls under hela den senare öppna förlängningsstudien. Även för de patienter som fick placebo under den dubbelblinda delen av studien och sedan Tesomet under den öppna förlängningsstudien påvisades minskningar av kroppsvikt och midjeomfång efter övergången till Tesomet.Saniona kommer att

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity23.11.2020 17:00:00 CETPress release

PRESS RELEASE November 23, 2020 Tesomet was well-tolerated in hypothalamic obesity patients throughout the duration of the 48-week trial (24 week double-blind [DB] followed by 24 week open label extension [OLE]), with no clinically meaningful differences in heart rate or blood pressure observed. All patients who entered the OLE study completed it.Patients receiving Tesomet for the full 48 weeks of the study demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference from baseline to Week 48, as well as improvements in glycemic control. Improvements observed in the DB period of the study were maintained over the duration of the OLE period. Patients who received placebo in the DB period of the study and were subsequently switched to Tesomet for the OLE period also achieved reductions in body weight and waist circumference after being switched to Tesomet.Saniona to host webcast with Dr. Ulla Feldt-Rasmussen on Tuesday, 24 November 202

Incap Corporation: Notification in accordance with chapter 9, section 10 of the securities market act on a change in holdings (Oy Etra Invest Ab)23.11.2020 16:30:00 CETPress release

Incap Corporation Stock Exchange Release 23 November 2020 at 5.30 p.m. (EET) Notification in accordance with Chapter 9, Section 10 of the Securities Market Act on a Change in Holdings (Oy Etra Invest Ab) Incap Corporation has on 23 November 2020 received a notification in accordance with the Securities Market Act, according to which the total holdings of shares and votes of Erkki Etola and the entities controlled by him (Tiiviste-Group Oy and Oy Etra Invest Ab) in Incap Corporation (FI0009006407) has increased over 20 percent threshold. Shareholder: Erkki Etola and entities controlled by him Position of previous notification: 19.20 % out of all shares and votes Date of change in holdings: 20 November 2020 Resulting situation on the date on which threshold was crossed: 1,327,333 shares, i.e. 22.81 % out of all shares and votes Incap Corporation's total number of shares amounts to 5,820,224 and each share has one vote. After November 20, 2020, Erkki Etola's direct holding of shares and v